SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases
This is a phaseⅡ, single-arm study evaluating the efficacy and safety of SHR-A1921 Combined with Bevacizumab in Triple-negative Breast Cancer with Brain Metastases
TNBC|Brain Metastasis
DRUG: SHR-A1921 + Bevacizumab
CNS ORR, The proportion of patients who have a CR or PR in the CNS, as determined by the Investigator according to RANO-BM criteria, from enrollment to progression or death (for any reason), assessed up to 24 months
CNS CBR, CNS clinical benefit rate (CBR) will be defined as the percentage of patients who experience a CR, PR or Stable Disease (SD) for at least 24 weeks., from enrollment to progression or death (for any reason), assessed up to 24 months|Progression-free survival, PFS will be defined as the time from the first dose of treatment to death or disease progression, Up to 2 years|Overall survival, OS will be defined as the time from the first dose of treatment to death for any cause, Up to 2 years|First progression site, The first lesion to progress, Up to 2 years|Safety as assessed by percentage of patients with any Adverse Event, Adverse event according to NCI-CTC AE 5.0, Up to 2 years
This is a phaseⅡ, single-arm study evaluating the efficacy and safety of SHR-A1921 Combined with Bevacizumab in Triple-negative Breast Cancer with Brain Metastases